Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04400058 · ClinicalTrials.gov registry record · Phase 3
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
A Phase 3 study, sponsored by Octapharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 207
- Enrollment target
NCT04400058 is a Phase 3 study that has completed, run by Octapharma. The registered enrollment target is 207 participants.
The verdict
NCT04400058, a Phase 3 study, has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 207 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease
Interventions
- OTHER Saline Solution
- BIOLOGICAL Octagam 10%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2022-02-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04400058
The ClinicalTrials.gov registry entry for NCT04400058 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline Solution is the first listed.
NCT04400058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04400058 about?
NCT04400058 is a clinical study titled "Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression". This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease
What is the current status of trial NCT04400058?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 207 participants. The study started on 2020-06-01. Estimated completion is 2022-02-01.
What interventions are being tested in trial NCT04400058?
The interventions under investigation include: Saline Solution (OTHER), Octagam 10% (BIOLOGICAL).
Who is sponsoring clinical trial NCT04400058?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.